Annual Meeting of the CAP-ACPcap-acp.com/2017/documents/astrazeneca_symposium.pdf · The...
1
AstraZeneca Sponsored Symposium Annual Meeting of the CAP-ACP Focusing the Canadian lens: Addressing the complexity of EGFR-T790M in NSCLC and PD-L1 biomarker testing Room: MacDonald Ballroom, Delta Prince Edward , Charlottetown, PEI Sunday 11 June 2017 • 12:00 – 13:30 Chair: Alan Spatz, Director of Pathology, Jewish General Hospital, Montreal LEARNING OBJECTIVES • Understand the clinical value of EGFR-T790M and PD-L1 testing and the future impact on patient management • Highlight the approaches to address the future challenges and opportunities for EGFR-T790M and PD-L1 testing The AstraZeneca logo is a registered trade-mark of AstraZeneca AB. Lunch will be provided. Please RSVP to [email protected] AGENDA New paradigms in the molecular pathology of NSCLC and the impact on clinical value for patients Mahmoud Abdelsalam, Head and Chair of Hematology / Oncology Division, Director of Oncology Clinical Trial, The Moncton Hospital, Moncton Future approaches to address the complexity of EGFR-T790M testing for patients with advanced NSCLC Alan Spatz, Director of Pathology, Jewish General Hospital, Montreal PD-L1 testing in NSCLC and beyond: A comparison of PD-L1 assays Michelle Downes, Director of Research, Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, Toronto Panel discussion and Q&A: Evolution of EGFR-T790M and PD-L1 testing; where do we go from here? Faculty and Audience
Transcript of Annual Meeting of the CAP-ACPcap-acp.com/2017/documents/astrazeneca_symposium.pdf · The...
AstraZeneca Sponsored Symposium
Annual Meeting of the CAP-ACP Focusing the Canadian lens: Addressing the complexity of
EGFR-T790M in NSCLC and PD-L1 biomarker testing
Room: MacDonald Ballroom, Delta Prince Edward , Charlottetown, PEI
Sunday 11 June 2017 • 12:00 – 13:30
Chair: Alan Spatz, Director of Pathology,Jewish General Hospital, Montreal
LEARNING OBJECTIVES
• Understand the clinical value of EGFR-T790M and PD-L1 testing and the future impact on patient management
• Highlight the approaches to address the future challenges and opportunities for EGFR-T790M and PD-L1 testing
The AstraZeneca logo is a registered trade-mark of AstraZeneca AB.
Lunch will be provided. Please RSVP to [email protected]
and PD-L1 testing
AGENDA
New paradigms in the molecular pathology of NSCLC and the impact on clinical value for patients
Mahmoud Abdelsalam, Head and Chair of Hematology / Oncology Division, Director of Oncology Clinical Trial, The Moncton Hospital, Moncton
Future approaches to address the complexity of EGFR-T790M testing for patients with advanced NSCLCAlan Spatz, Director of Pathology, Jewish General Hospital, Montreal
PD-L1 testing in NSCLC and beyond: A comparison of PD-L1 assaysMichelle Downes, Director of Research, Department of Anatomic Pathology, Sunnybrook
Health Sciences Centre, Toronto
Panel discussion and Q&A: Evolution of EGFR-T790M and PD-L1 testing; where do we go from here?
Faculty and Audience
